Thalidomide, referred to phocomelia, has been introduced as an anti‐inflammatory therapy with remarkable efficacy in many autoimmune disorders, such as psoriasis, systemic lupus erythematosus, and inflammatory bowel disease, in which the suppressive effect of thalidomide on the pro‐inflammatory cytokines, including interleukin (IL)‐6, tumor necrosis factor (TNF)‐α, and interferon (IFN), was revealed.8, 9, 10. This evidence concerns the gene TNF and systemic lupus erythematosus.